Showing 4091-4100 of 5314 results for "".
- Aesthetic Management Partners Launches New Non-Surgical Skin Revitalization Systemhttps://practicaldermatology.com/news/aesthetic-management-partners-launches-new-non-surgical-skin-revitalization-system/2475272/Aesthetic Management Partners announced the launch of PLADUOpro, a dual argon and nitrogen gas plasma system designed for advanced skin restoration, earlier this month.
- Elevated IFN Signatures Seen in Nonlesional Skin of Cutaneous Lupus Erythematosus Patientshttps://practicaldermatology.com/news/elevated-ifn-signatures-seen-in-nonlesional-skin-of-cle-patients/2475210/Patients with systemic lupus erythematosus (SLE) and a history of cutaneous lupus erythematosus (CLE) showed elevated interferon-stimulated gene (ISG) expression in blood and nonlesional skin, according to a new study. The si
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475018/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475019/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://practicaldermatology.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.